Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes

被引:17
作者
Kim, KM
Kim, HW
Kim, JO
Baek, KM
Kim, JG
Kang, CY
机构
[1] Seoul Natl Univ, Immunol Lab, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Med, Seoul 151742, South Korea
关键词
D O I
10.1046/j.1365-2567.2002.01538.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
4-1BB(CD137) is a member of the tumour necrosis factor receptor superfamily and is expressed on activated T cells, monocytes and natural killer (NK) cells. The interaction of 4-1BB and 4-1BB ligand provides a costimulatory signal leading to T-cell activation. The expression of 4-1BB has been known to be activation dependent. Interestingly, we found that expression of 4-1BB increased in human peripheral blood mononuclear cells after exposure to mitomycin C. Thus, we tested whether the treatment with other DNA-damaging agents, such as doxorubicin, bleomycin, and gamma-irradiation, could induce 4-1BB expression. The data indicated that 4-1BB expression increased dose-dependently by these agents reaching maximum at 2-3 days after the exposure. We found that the major 4-1BB-expressing population was CD3(+) T cells, although a moderate number of CD14(+) cells and a few NKB1(+) cells also expressed 4-1BB. The levels of 4-1BB expression induced by anticancer drugs, were relatively lower than that induced by CD3 ligation. Interestingly, at subcytotoxic concentrations, doxorubicin and bleomycin considerably enhanced 4-1BB expression induced by CD3 ligation in CEM cells. The ligation of the damage-induced 4-1BB by monoclonal antibody enhanced the viability and proliferating capacity of the cells. In conclusion, the expression of 4-1BB might be one of the cellular responses of the immune cells against various genotoxic stresses.
引用
收藏
页码:472 / 479
页数:8
相关论文
共 55 条
[31]   Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism [J].
Mokyr, MB ;
Kalinichenko, TV ;
Gorelik, L .
CELLULAR IMMUNOLOGY, 1997, 178 (02) :152-161
[32]  
MOKYR MB, 1989, CANCER RES, V49, P4597
[33]   CELLULAR PHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA - COMPARISON OF BOLUS ADMINISTRATION AND CONTINUOUS-INFUSION [J].
MULLER, C ;
CHATELUT, E ;
GUALANO, V ;
DEFORNI, M ;
HUGUET, F ;
ATTAL, M ;
CANAL, P ;
LAURENT, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (05) :379-384
[34]   p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs [J].
Müller, M ;
Wilder, S ;
Bannasch, D ;
Israeli, D ;
Lehlbach, K ;
Li-Weber, M ;
Friedman, SL ;
Galle, PR ;
Stremmel, W ;
Oren, M ;
Krammer, PH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (11) :2033-2045
[35]  
NAGARKATTI M, 1989, CANCER RES, V49, P6587
[36]  
NORTH RJ, 1990, IMMUNOLOGY, V71, P90
[37]   REGULATION OF 4-1BB EXPRESSION BY CELL-CELL INTERACTIONS AND THE CYTOKINES, INTERLEUKIN-2 AND INTERLEUKIN-4 [J].
POLLOK, KE ;
KIM, SH ;
KWON, BS .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (02) :488-494
[38]   4-1BB T-CELL ANTIGEN BINDS TO MATURE B-CELLS AND MACROPHAGES, AND COSTIMULATES ANTI-MU-PRIMED SPLENIC B-CELLS [J].
POLLOK, KE ;
KIM, YJ ;
HURTADO, J ;
KIM, KK ;
KWON, BS ;
ZHOU, Z .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (02) :367-374
[39]  
POLLOK KE, 1993, J IMMUNOL, V150, P771
[40]  
SAHASRABUDHE DM, 1986, J BIOL RESP MODIF, V5, P581